{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:33:21Z","timestamp":1786700001447,"version":"build-2736575974"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: A considerable proportion of patients with asthma remain inadequately controlled despite treatment with inhaled corticosteroid\/long-acting \u03b22-agonist (ICS\/LABA) therapy. Single-inhaler triple therapy comprising an inhaled corticosteroid, a long-acting \u03b22-agonist, and a long-acting muscarinic antagonist (ICS\/LABA\/LAMA) has emerged as an effective step-up treatment; however, real-world evidence remains limited. This study aimed to evaluate the effects of transitioning from high-dose ICS\/LABA therapy to single-inhaler triple therapy on asthma control, lung function, and exacerbation-related outcomes in routine clinical practice. Materials and Methods: This retrospective observational study included adult patients with uncontrolled asthma who were switched from high-dose ICS\/LABA therapy to single-inhaler triple therapy at a tertiary referral center. Demographic characteristics, Asthma Control Test (ACT) scores, pulmonary function tests, blood eosinophil counts, exacerbation frequency, oral corticosteroid (OCS)-requiring exacerbations, short-acting \u03b22-agonist (SABA) use, emergency department visits, and hospitalizations were compared before and after treatment escalation using paired statistical analyses. Results: Nineteen patients (mean age 58.9 \u00b1 10.4 years; 63.2% female) were included. Following transition to single-inhaler triple therapy, asthma control improved significantly, with mean ACT scores increasing from 14.8 \u00b1 3.2 to 23.4 \u00b1 3.6 (p &lt; 0.001). Mean forced expiratory volume in one second (FEV1) increased from 1692.6 \u00b1 722.7 mL to 2020.5 \u00b1 871.5 mL, while predicted FEV1 improved from 64.2 \u00b1 21.2% to 75.6 \u00b1 21.6% (both p &lt; 0.001). Total annual exacerbation frequency decreased from a median of 2 (interquartile range [IQR], 1\u20133) to 0 (IQR, 0\u20131; p = 0.0005), and 78.9% of patients experienced at least one fewer exacerbation. Significant reductions were also observed in OCS-requiring exacerbations, SABA use, emergency department visits, hospitalizations, and blood eosinophil counts. Conclusions: In this real-world cohort, transitioning from ICS\/LABA therapy to single-inhaler triple therapy was associated with statistically significant improvements in asthma control and lung function, together with substantial reductions in exacerbation burden and healthcare utilization. These findings support the effectiveness of single-inhaler triple therapy as a step-up treatment strategy for patients with uncontrolled asthma in routine clinical practice.<\/jats:p>","DOI":"10.3390\/medicina62081557","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"1557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes Following Transition from ICS\/LABA to Single-Inhaler Triple Therapy in Patients with Uncontrolled Asthma: A Real-World Cohort Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3957","authenticated-orcid":false,"given":"Melis","family":"Ya\u011fd\u0131ran","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Ankara Atat\u00fcrk Sanatorium Training and Research Hospital, University of Health Sciences, Ankara 06290, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-1158","authenticated-orcid":false,"given":"Kurtulu\u015f","family":"Aksu","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Ankara Atat\u00fcrk Sanatorium Training and Research Hospital, University of Health Sciences, Ankara 06290, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Asthma (GINA) (2025). Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma. Available online: https:\/\/ginasthma.org\/2025-gina-strategy-report\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","article-title":"Burden of asthma among patients adherent to ICS\/LABA: A real-world study","volume":"56","author":"Davis","year":"2019","journal-title":"J. Asthma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","article-title":"Asthma control and disease burden in patients with asthma and allergic comorbidities","volume":"55","author":"Lee","year":"2018","journal-title":"J. Asthma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3109\/02770903.2015.1056350","article-title":"Fluticasone furoate\/vilanterol (100\/25 \u03bcg or 200\/25 \u03bcg) versus fluticasone furoate in persistent asthma","volume":"52","author":"Bernstein","year":"2015","journal-title":"J. Asthma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in inadequately controlled asthma (CAPTAIN): A double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","article-title":"Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): Two double-blind, parallel-group, randomised, controlled phase 3 trials","volume":"394","author":"Virchow","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2004233","DOI":"10.1183\/13993003.04233-2020","article-title":"Triple therapy in uncontrolled asthma: A network meta-analysis of phase III studies","volume":"58","author":"Rogliani","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2018.2757","article-title":"Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: A systematic review and meta-analysis","volume":"319","author":"Sobieraj","year":"2018","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: Toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_11","first-page":"109","article-title":"Dual bronchodilation in airway diseases","volume":"145","author":"Cazzola","year":"2014","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/17476348.2019.1657408","article-title":"A potential role of triple therapy for asthma patients","volume":"13","author":"Cazzola","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107368","DOI":"10.1016\/j.rmed.2023.107368","article-title":"TRIVOLVE study: Single-inhaler extrafine LABA\/LAMA\/ICS therapy and treatment adherence in asthma","volume":"218","author":"Brusselle","year":"2023","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1701126","DOI":"10.1183\/13993003.01126-2017","article-title":"A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma","volume":"51","author":"Sulaiman","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00075614","article-title":"Medication adherence and the risk of severe asthma exacerbations: A systematic review","volume":"45","author":"Engelkes","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","article-title":"Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD","volume":"107","author":"Backer","year":"2013","journal-title":"Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Asthma Control and Exacerbations\u2014Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1208606","article-title":"Tiotropium in asthma poorly controlled with standard combination therapy","volume":"367","author":"Kerstjens","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100439","DOI":"10.1016\/j.opresp.2025.100439","article-title":"Triple therapy in asthma","volume":"7","year":"2025","journal-title":"Open Respir. Arch."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.opresp.2025.100442","article-title":"Expert consensus on single-inhaler triple therapy for the treatment of asthma in adult patients","volume":"7","author":"Serrano","year":"2025","journal-title":"Open Respir. Arch."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1901872","DOI":"10.1183\/13993003.01872-2019","article-title":"Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study","volume":"55","author":"Nwaru","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kushima, Y., Shimizu, Y., Arai, R., Chibana, K., Shimizu, Y., Amagai, M., Takemasa, A., Ikeda, N., Masawa, M., and Kushima, A. (2025). Real-life effectiveness of once-daily single-inhaler triple therapy (FF-UMEC-VI) after switching from dual therapy (ICS-LABA) in patients with symptomatic asthma: Trelegy Ellipta for Real Asthma Control Study. Front. Allergy, 6.","DOI":"10.3389\/falgy.2025.1537501"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s41030-025-00288-0","article-title":"A brief report on a systematic review of real-world effectiveness studies of ICS\/LAMA\/LABA for treatment of adults with asthma in the US","volume":"11","author":"Noorduyn","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s12325-024-03083-6","article-title":"Medicare advantage population in the United States: Outcomes of patients with asthma treated with ICS\/LABA before and after initiation with fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI)","volume":"42","author":"Baptist","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update: An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: A post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma exacerbation Rate","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaip.2024.01.039","article-title":"Baseline characteristics and ICS\/LAMA\/LABA response in asthma: Analyses from the CAPTAIN study","volume":"12","author":"Boulet","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jaip.2024.05.019","article-title":"Characterization of moderate and severe asthma exacerbations in the CAPTAIN study","volume":"12","author":"Oppenheimer","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/all.15076","article-title":"Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications","volume":"77","author":"Agusti","year":"2022","journal-title":"Allergy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.jaip.2022.06.010","article-title":"Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management","volume":"10","author":"Busse","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s41030-024-00285-9","article-title":"Retrospective cohort study of elderly users of single- or multiple-inhaler triple therapy for the treatment of asthma in the USA","volume":"11","author":"Settipane","year":"2025","journal-title":"Pulm. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.resinv.2025.04.017","article-title":"Analysis of adherence to ICS\/LAMA\/LABA in patients with asthma: A retrospective observational cohort study using medical claims data","volume":"63","author":"Oga","year":"2025","journal-title":"Respir. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2021.7872","article-title":"Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/02770903.2024.2366523","article-title":"Asthma remission one, none and one-hundred thousand: The relevance of the patient\u2019s view","volume":"61","author":"Bonini","year":"2024","journal-title":"J. Asthma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"240181","DOI":"10.1183\/16000617.0181-2024","article-title":"Pro: Clinical remission in asthma\u2014Implications for asthma management","volume":"34","author":"Principe","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/resp.70077","article-title":"The risk\u2013benefit balance of oral corticosteroid treatment for asthma attacks: A discrete choice experiment of patients and healthcare professionals in the UK and New Zealand","volume":"30","author":"Howell","year":"2025","journal-title":"Respirology"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:54:30Z","timestamp":1786697670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081557"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081557","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}